



March 21, 2019

**BSE Limited**

P. J. Towers  
Dalal Street,  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza  
Bandra Kurla Complex  
Bandra (E),  
Mumbai - 400 051

Dear Sirs,

We enclose a communication pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Life Sciences Ltd.**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubl.com](http://www.jubl.com)

## **USFDA Inspection Update - API Facility at Nanjangud**

***Noida (UP), India, Thursday, March 21, 2019***

Jubilant Lifesciences Limited (JLL), an integrated global pharmaceuticals and life sciences company, has been informed by the U.S. Food and Drug Administration (USFDA), in correspondence dated March 13, 2019, received today, that the inspection from December 10-18, 2018 at the Jubilant Generics Limited (JGL) (FEI: 3003144728) API manufacturing facility, in Nanjangud, Mysore, has been classified as “Official Action Indicated” (OAI). The USFDA also stated that the facility might be subject to a cGMP regulatory or enforcement action based on this inspection, and that FDA could withhold approval of any pending applications or supplements in which this facility is listed.

FDA’s announcement will not have any impact on the existing revenues from operations of this facility. We believe that this letter has been issued as part of a USFDA initiative to respond to the company within 90 days of the inspection, regarding the facility’s status. As per the agency’s internal procedures, the company can engage with the agency within 40 days to seek to get the decision downgraded from the OAI classification. In that regard, Jubilant is in the process of sending a further update to USFDA of its corrective actions regarding the agency’s inspectional observations from December 2018.

### **About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and other businesses including Drug Discovery Solutions and India Branded Pharmaceuticals. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectibles and Non-sterile products through 5 USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radio-pharmacies in the US. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions business, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 2 world class research centers in India. Jubilant Life Sciences Limited has a team of around 7,600 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).



**For more information, please contact:**

**For Investors**

Ravi Agrawal / Vineet Mayer  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: ravi.agrawal@jubl.com  
Vineet.mayer@jubl.com

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Ph: +91 22 6645 1209 / 1220  
E-mail: siddharth@cdr-india.com  
[karl@cdr-india.com](mailto:karl@cdr-india.com)

*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. For detailed disclaimer in case of Jubilant Pharma Limited, please visit <http://www.jubilantpharma.com/fullpage.aspx?mpgid=1147&pgid=1147>*